Evidence map›Paper›PMID 29556135›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2018

Suresh Palanivel, Anastasia Zhurina, Phuong Doan, Jerome G Chandraseelan, Vinoth Kumar Megraj Khandelwal, Fedor I Zubkov, Kamran T Mahmudov, Armando J L Pombeiro, Olli Yli-Harja, Meenakshisundaram Kandhavelu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 5 countries.

Suresh PalanivelMolecular Signaling Lab, CSB, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Anastasia ZhurinaMolecular Signaling Lab, CSB, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Phuong DoanMolecular Signaling Lab, CSB, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Jerome G ChandraseelanMolecular Signaling Lab, CSB, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Vinoth Kumar Megraj KhandelwalDepartment of Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.
Fedor I ZubkovOrganic Chemistry Department, RUDN University, 6 Miklukho-Maklaya St., Moscow 117198, Russian Federation.
Kamran T MahmudovCentro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
Armando J L PombeiroCentro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
Olli Yli-HarjaComputational Systems Biology Group, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Meenakshisundaram KandhaveluMolecular Signaling Lab, CSB, BioMediTech Institute and Faculty of Biomedical Sciences and Engineering, Tampere University of Technology, P.O. Box 553, 33101 Tampere, Finland.
Tampere University · FIUniversity of Lisbon · PTMario Negri Sud Foundation · ITPeoples' Friendship University of Russia · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arylhydrazones of active methylene compounds (AHAMCs) are potent chemotherapy agents for the cancer treatment. AHAMCs enhance the apoptotic cell death and antiproliferation properties in cancer cells. In this study, a series of AHAMCs, 13 compounds, was assayed for cytotoxicity, apoptosis, externalization of phosphatidylserine, heterogeneity and cellular calcium level changes. The

Indexed as

ApoptosisArylhydrazones of active methylene compoundsChemotherapyCytotoxic effectGliomaImmortal cellsSingle cell analysis

Identifiers

PMID29556135
PMCPMC5856940
OpenAlexW2782329283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.